Zion Market Research has published a new report titled “Enzyme Replacement Therapy Market by Enzyme (pegademase, velaglucerase alfa, agalsidase beta, imiglucerase, taliglucerase, laronidase, alglucosidase alfa, and other enzymes), therapeutic condition (Pompe’s disease, Gaucher’s disease, MPS, Fabry’s disease, SCID, and others), Route of administration (oral and parenteral) and End user (hospitals, infusion centers, and others): Global Industry Perspective, Comprehensive Analysis and Forecast, 2019 – 2025”.
According to the report, global demand for Enzyme Replacement Therapy Market was valued at approximately USD 6462.6 Million in 2018, and is expected to generate revenue of around USD 9581.64 Million by end of 2025, growing at a CAGR of around 5.81% between 2018 and 2025.
Enzymes are molecules that perform in different biochemical reactions catalytic functions in the body. Lysosomal Storage Disease (LSD) is caused by body enzyme deficiency and contributes to inflammation of the body’s organs. Enzyme replacement therapy is the method of replacing enzymes with artificial enzymes for patients with enzyme deficiency. The therapy is performed by the preparation-containing enzyme by intravenous infusion or oral administration. Enzyme replacement therapies are intended to increase the concentration of enzymes, but not to alter the underlined disease root. Enzyme replacement therapy is currently available for conditions such as Hunter syndrome, Fabry disease, digestive diseases, and Gaucher disease.
Request Free Sample is Available @ https://www.zionmarketresearch.com/sample/enzyme-replacement-therapy-market
Due to factors such as wider availability of therapy, ease of enzyme replacement therapy approval guidelines, and benefits such as fewer side effects, the global market for enzyme replacement therapy is likely to experience high growth over the forecast period. Already expected to drive market growth are factors such as easy access to enzyme replacement therapy, and government funding for care. Nonetheless, insurance issues in various countries and less side effects of therapy can have a significant impact on the success of enzyme replacement therapy.
The market for Enzyme Replacement Therapy is segmented based on enzyme, therapeutic condition, route of administration, end user, and region. Based on Enzyme, the market is segmented into pegademase, velaglucerase alfa, agalsidase beta, imiglucerase, taliglucerase, laronidase, alglucosidase alfa, and other enzymes. The highest incidence of Gaucher disease is one of the key factors for the large market share of enzymes like imiglucerase and velaglucerase alfa. Improved use of pancreatic enzymes such as amylase, lipase, and protease is used to diagnose exocrine pancreatic insufficiency (EPI) usually seen in cancer patients.
On the basis of therapeutic condition, the market is bifurcated Pompe’s disease, Gaucher’s disease, MPS, Fabry’s disease, SCID, and others. Gaucher’s disease has a high incidence due to its large market share. Gaucher disease is a disease caused by recessive mutation that is inherited. On the basis of the route of administration segment, the market is bifurcated into oral and parenteral. Due to its ability to promote rapid absorption and drug delivery, the parenteral route of administration held the largest market share in 2018. Based on the end user segment, the market is bifurcated into hospitals, infusion centers, and others. Hospitals are the primary care facilities for a wide range of diseases which promote quick diagnosis. These end-use settings therefore held the largest market share due to frequent patient visits and their ability to cater for a variety of lysosomal storage diseases. During the forecast period, infusion centers are expected to gain the highest CAGR. Since these centers are specialized centers for IV infusions, they facilitate a wide range of inherited diseases for easy treatment.
Geographic segmentation includes the current and forecast demand for Asia Pacific, North America, Latin America, Europe, and Middle East & Africa with its further bifurcation into major countries. In 2018, North America dominated the market. Well-developed healthcare infrastructure and the rise of the leading market players in North America have powered growth in the regional segment. Moreover, the adoption of advanced technologies and increased focus on drug development in this region are expected to drive growth in the sector.
Some of the players included in Enzyme Replacement Therapy market are Sanofi, Shire, Alexion, Pfizer, Digestive Care, Leadiant Biosciences Allergan, BioMarin, AbbVie, Horizon Pharma, Johnson & Johnson Actelion, Recordati Rare Diseases, amongst others.
The report segments global Enzyme Replacement Therapy market as follows:
Global Enzyme Replacement Therapy Market: Enzyme Segment Analysis
Global Enzyme Replacement Therapy Market: Therapeutic Condition Segment Analysis
Global Enzyme Replacement Therapy Market: Route of Administration Segment Analysis
Global Enzyme Replacement Therapy Market: End user Segment Analysis
Global Enzyme Replacement Therapy Market: Regional Segment Analysis
To view TOC of this report is available upon request @ https://www.zionmarketresearch.com/toc/enzyme-replacement-therapy-market